Forte Biosciences Inc (FBRX)

Forte Biosciences Announces Pricing of $150 Million Public OfferingApril 8, 2026 9:30 PM
Business Wire
Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,709,936 shares of its common stock at a price to the public of $26.27 per share. In addition, Forte has granted the underwriters a 30-day option to purchase up to an additional 856,490 shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock are being offered by Forte.


The gross proceeds from the offering are expected to be approximately $150 million before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about April 10, 2026, subject to satisfaction of customary closing conditions.


Forte intends to use the net proceeds of the offering for working capital and other general corporate purposes, which includes funding clinical development of its product candidate and other research activities.


Guggenheim Securities and Barclays are acting as joint book-running managers for the offering.


The offering is being made pursuant to a Registration Statement on Form S-3 (File No. 333-286226), including a base prospectus, previously filed with and declared effective by the SEC. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering has been filed with the SEC. A final prospectus supplement and accompanying prospectus relating to the offering will also be filed with the SEC. These documents can be accessed for free through the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the offering, when available, may also be obtained from Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com, and Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 by calling 1-888-603-5847 or by email at barclaysprospectus@broadridge.com.


This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.


About Forte


Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.


Forward Looking Statements


Forte cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the Forte’s current beliefs and expectations. Forward-looking statements include statements regarding the completion and timing of the offering and the anticipated use of proceeds from the offering. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: whether or not Forte will be able to raise capital through the sale of securities or consummate the offering; the final terms of the offering; the satisfaction of customary closing conditions; prevailing market conditions; general economic and market conditions as well as geopolitical developments; and other risks. Additional risks, uncertainties, and other information affecting Forte’s business and operating results are contained in Forte’s Annual Report on Form 10-K filed on March 31, 2026, and in its other filings with the Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Forte undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.


Source: Forte Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260408582507/en/
Forte Biosciences, Inc.

investors@fortebiorx.com


Original: Forte Biosciences Announces Pricing of $150 Million Public Offering

Forte Biosciences Announces Proposed Public OfferingApril 8, 2026 4:02 PM
Business Wire
Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock. All of the shares of common stock are being offered by Forte. The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.


Forte intends to use the net proceeds of the offering for working capital and other general corporate purposes, which includes funding clinical development of its product candidate and other research activities.


Guggenheim Securities is acting as book-running manager for the offering.


The offering is being made pursuant to a Registration Statement on Form S-3 (File No. 333-286226), including a base prospectus, previously filed with and declared effective by the SEC. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and copies of which, when available, can be accessed for free through the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available, may also be obtained from Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.


This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.


About Forte


Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.


Forward Looking Statements


Forte cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the Forte’s current beliefs and expectations. Forward-looking statements include statements regarding the completion, timing, and size of the offering, Forte’s intent to grant the underwriters a 30-day option to purchase additional shares, and the anticipated use of proceeds from the offering. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: whether or not Forte will be able to raise capital through the sale of securities or consummate the offering; the final terms of the offering; the satisfaction of customary closing conditions; prevailing market conditions; general economic and market conditions as well as geopolitical developments; and other risks. Additional risks, uncertainties, and other information affecting Forte’s business and operating results are contained in Forte’s Annual Report on Form 10-K filed on March 31, 2026, and in its other filings with the Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Forte undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.


Source: Forte Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260408701715/en/
Forte Biosciences, Inc.

investors@fortebiorx.com


Original: Forte Biosciences Announces Proposed Public Offering

Very unusual volume, looks like pending news on data to be released this quarter.

Ooooooops!! (Now look what you've done to me, Boss!!! See me below, live right now!!! DAMN-IT!!!)

Not in it resistance $18 some selling now 

FBRX: O.K., then you're crackin' for LUNCH today; and I'll crack for DINNER, Homeboy!!

FBRX: This will hit $50+ frickin' bucks today!!!

I'll take $20 - $25 and see you later 

18s weeeeee

FBRX: It's that MICRO-Float, & a $64 (short-term) price prediction by Wall Street!!

15.98s 

145%...... 14.52s

nice 100% up 12.10 52 high 21.25s 

FBRX, new 52 week low

Lots of insider activity at Forte since the last post here on October 2023...

FBRX new 52 week low

FBRX new 52 week low

FBRX new 52 week low

FBRX new 52=week low

FBRX new 52 week low

Huge volume today

Big step above 1,32

Interesting

More

Ooooo looking for another squeeze but also, offering ideally in 2-3-3.5 range . No idea but. Undervalued

Short squeeze upcoming

Support forming down here?

FBRX- this stock is DEAD

RIP

I lost more than 900k in eeenf! I didn't file lawsuit...u think a mistake???

do you have more than $100,000 in losses? if not, that lawsuit doesnt pertain to you.

LOS ANGELES, September 08, 2021--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Forte Biosciences, Inc. ("Forte" or "the Company") (NASDAQ: FBRX) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Forte announced after the market closed on September 2, 2021, that "topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI)." Based on this news, shares of Forte crashed by more than 80% on September 3, 2021.

Yet again fill my order 4.35 and take it down....this is frustrated me...I better trade penny

In 4.35

short covering alone should make this practically double soon..

or just pick a good entry point and hold for a few days

if they take this under $4.00 tomorrow, I have to buy one last time, fully aware that this stock may never bounce again, and/or be delisted

Afraid this go below 4 tomorrow! I hate daytrade Nasdaq too! 3-5 I lost daytrading it! Always after they fill my big order thank it goes down! Freaking mm! 3 times today after they fill my order than up 2 tick than someone wack it down fast! Frustrated me hold it... I decided stay outside watch until I see solid activity!

that's why I rarely day trade, maybe once a month or so. I love to swing trade and hold overnight, days, weeks etc

definitely an ugly continuation from friday

i only bought 1000 at $4.95 on friday

will see how this is trading tomorrow in pre-market, but I wont buy more than another 1000 shares above $4.25, so any break below $4.00 and the gamble is on, mostly likely, this stock will bounce once then die

True, I'm just going by the 3-day rule, and normally the third day it doesn't move very much, more like a balancing act. Normally the biggest damage is the first two days. So since I bought close to the bottom even if it hits $4 tomorrow, I won't be selling. If it goes lower then I'll reconsider

Buy 4.68 this morning sold 4.30 lost.....very hard to pick bottom here....I enter 3 times 3 time sell lost

ooooops, yes, 4.15, sorry about that... I do not see this going much lower than todays lows, but if it does tomorrow, I will buy more... even with the " not so good" trial results, I think this will go to 12-15 in very short order..this cannot be the only think they have their feet into, so I think they will do fine ... institutions are masters at burying something for stupid reasons, just to buy back at the lows and ride it up again....

$3.15? you mean $4.15?

i did, 21k @ 3.15 avg....hoping this goes well.....

100% gamble-falling knife play

nothing more

Try pick bottom...u think bottom??

Forte Biosciences previously reported that it had cash and cash equivalents of $50.8 million as of June 30, 2021.

https://finance.yahoo.com/news/clinical-trial-fb-401-treatment-200500416.html

the entire float nearly traded 4x yesterday

https://finviz.com/quote.ashx?t=fbrx

10.34M float

anyone else snag some under $5?

Took a smaller size for the weekend hold. I hope the gamble pays off. We shall see.

This tank similar to my eeenf tank my portfolio in June! Wow

HORRENDOUS DUMPING